|Day's Range||8.22 - 8.51|
|52 Week Range||3.10 - 13.40|
|PE Ratio (TTM)||-11.65|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q3 2017 Array Biopharma Inc Earnings Call
Following Array Biopharma Inc (NASDAQ: ARRY ) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks ...
Array Biopharma's financial results get the back seat today, while clinical-trial results ride shotgun.